Interference of CD38 monoclonal antibody in blood compatibility testing and its countermeasures: A general consensus among experts / 中国输血杂志
Jianqing MI; Xiaohong CAI; Shaoyuan WANG; Lihua HU; Ting NIU; Deqing WANG; Chengcheng FU; Chunyan SUN; Dong XIANG; Wen GAO; Tianhong MIAO; Liye ZHONG; Baohua QIAN; Gang AN; Rong XIA; Rong GUI; Jing LIU; Xiaofeng TANG; Jue XIE; Jia GAN; Jiang WU; Danhui FU; Li QIN; Jian HOU; Xuefeng WANG.
Chinese Journal of Blood Transfusion
; (12): 327-334, 2021.
Artículo
en Zh
| WPRIM | ID: wpr-1004515
With continuous discovery of tumor immune targets and continuous changes in antibody research and development technology, antibody drugs are becoming more and more widely used in clinical practice. However, some targets are not only expressed on tumor cells, but also on red blood cells. Therefore, the clinical application of antibodies against the corresponding targets may interfere with the detection of blood transfusion compatibility, resulting in difficulty in blood matching or delay of blood transfusion. This consensus summarizes the current solutions for the interference of CD38 monoclonal antibody (CD38 mAb) in transfusion compatibility testing. After analyzing the advantages and disadvantages of different methods, polybrene and sulfhydryl reducing agents [dithiothreitol (DTT) or 2-mercaptoethanol (2-Me)], as a solution for CD38 mAb interference in blood compatibility testing, are recommended for Chinese patients, so as to eliminate blood transfusion interference produce by CD38 mAb and further provide a pre-transfusion workflow for clinicians and technicians in Department of Blood Transfusion.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados